Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.
Mount Sinai Liver Cancer Program, Division of Liver Diseases, ICAHN School of Medicine at Mount Sinai, New York, NY 10029, USA; HCC Translational Research Lab, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona. Barcelona 08036, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona 08036, Catalonia, Spain. Electronic address: josep.llovet@mssm.edu.
Josep M
JM
Llovet
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D049109:Cell Proliferation; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005784:Gene Amplification; D017228:Hepatocyte Growth Factor / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008264:Macrophages; D051379:Mice; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D017228:Hepatocyte Growth Factor; D000077157:Sorafenib